Table 1.

Stromal ECM factors and their clinical relevance/prognostic value in cancer

FactorExpressionClinical significanceCancer
Oncofetal fibronectinStromaMalignancy, poor prognosisOral (53), ovarian (54), colorectal (55), breast (56)
TGF-βstromaMortality, tumor growthProstate (11), breast (12)
SDF-1CAFsTumor progression, angiogenesisBreast (1, 2)
HB-EGFStroma, CAFsTumor growthCervical (31), prostate (32)
Tenascin-C, -WStromaMalignancy, metastasisBreast (60, 64, 71)
MMP-2Stroma, seraPoor prognosis, metastasis, invasionNSCLC (86), prostate (88), skin SCC (93)
MMP-13Myofibroblasts, stromaPoor prognosis, invasionSkin (93), HNSCC (99), colorectal (100), breast (102)
MMP-11Fibroblasts, stromaLocal invasivenessBreast (47), HNSCC (101)
Adam-9MyofibroblastsMetastasisColorectal (104)
Adam-12StromaTumor progressionProstate (105)
PAI-1, uPATumor and stromaPoor prognosisBreast (117, 118)
PAI-2Tumor and stromaFavorable prognosisBreast (117, 119)
WFDC-1CAFs (decreased)MetastasisProstate (121)
Syndecan-1StromaProgression, poor survivalOvarian (128), endometrial (130), breast (134)
VersicanStromaMalignancy, progressionOvarian (141), prostate (142)
Decorin protein coreMyofibroblastsTumor suppressionTriple-negative breast (147)
HyaluronanStromaPoor survival, metastasisOvarian (159), breast (160), prostate (161), NSCLC (162)
ICAMCAFsProgressionNSCLC (51)
VCAMCAFsMetastasisColorectal (52)
α11β1FibroblastsTumorigenicityNSCLC (26)
CD10 (MME)CAFs, stromaProgression, poor prognosis, recurrenceNSCLC (51), melanoma (108), breast (109)
PodoplaninCAFs1. Poor prognosisBreast (187, 188), lung (189), esoph. (190) Colorectal (191)
2. Favorable prognosis
PAR-1StromaProgressionProstate (192)
Osteonectin (SPARC)Stroma1. Recurrence, poor prognosisBreast (199), pancreatic (194)
2. Reduced metastasisBladder (200)
OsteopontinStromaTumor progressionBreast (204)
PeriostinStroma1. Favorable prognosisBreast (47)
2. Poor prognosis, progressionProstate (47, 214)